SynthesisJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024
Dosimetry of [
Synthesis in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Tumor and Organ Dose Estimates fromJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Dosimetry Analysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Trial
- Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Influence of increased injected activities up 9.0 GBq [EJNMMI physics · 2026Article
- Organ and tumor dosimetry of [European journal of nuclear medicine and molecular imaging · 2026Article
- Overall Survival with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Tolerability of [European journal of nuclear medicine and molecular imaging · 2026Article
- Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.Acta oncologica (Stockholm, Sweden) · 2026Article
- Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [European journal of nuclear medicine and molecular imaging · 2026Article
- First-in-human evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Dosimetry of [EJNMMI research · 2026Article
- Investigation of iterative deconvolution inEJNMMI physics · 2026Article
- Enhanced data usability in dynamicEJNMMI physics · 2026Article
- Safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2026Article
- Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (Journal of clinical medicine · 2026Review
- Future of radiotheranostics.BMJ oncology · 2026Review
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
Corrections and comments
Authors and funding
5 authors.
Funding
Abstract
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.